Capstone Therapeutics Corp.

Q: Sep 30 2025

Q: Jun 30 2026

Q: Mar 31 2026

Q: Jun 30 2025

Q: Mar 31 2026

Q: Mar 31 2026

FY: Dec 31 2024

FY: Dec 31 2025

FY: Dec 31 2025

FY: Dec 31 2025

Q: Sep 30 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Jun 30 2019

Q: Mar 31 2019

FY: Dec 31 2018

Q: Sep 30 2018

Results of Operations and Financial Condition

Regulation FD Disclosure

Regulation FD Disclosure

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Other Events

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Financial Statements and Exhibits

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Notice of Effectiveness

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

Registration (IPO) statement under Securities Act of 1933

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement with Pricing Information

Notice of Effectiveness

Amended Initial Registration Statement

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement with Pricing Information

Certification of approval for listing and registration on a national securities exchange

Notice of Effectiveness

Registration of Securities on Exchange

Free Writing Prospectus

Free Writing Prospectus

Amended Initial Registration Statement

No description available

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

No description available

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

No description available

Definitive Proxy Statement

No description available

Preliminary Proxy Statement

Definitive Proxy Statement

Preliminary Proxy Statement

Definitive Proxy Statement

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

FELDMAN FREDRIC J

TOPOREK MICHAEL

Strout Gordon Lewis Jr

SCHULTZ EDWARD CHRISTOPHER

Lipman Matthew E.

HOWSE ELWOOD D

HOLLIMAN JOHN M III

Grotke Kevin Allan

TOPOREK MICHAEL

TOPOREK MICHAEL

TOPOREK MICHAEL

HOWSE ELWOOD D

Grotke Kevin Allan

Lipman Matthew E.

Lipman Matthew E.

Strout Gordon Lewis Jr

SCHULTZ EDWARD CHRISTOPHER

3i, LP

Lipman Matthew E.

TOPOREK MICHAEL

Definitive information statement

Annual Report Scanned (Paper)

Definitive information statement

Annual Report Scanned (Paper)

Definitive information statement

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No description available

Draft registration statement (confidential submission) (amendment)

Letter from the SEC